L
Luisa Craviotto
Researcher at University of Parma
Publications - 19
Citations - 231
Luisa Craviotto is an academic researcher from University of Parma. The author has contributed to research in topics: Multiple myeloma & Bone marrow. The author has an hindex of 6, co-authored 17 publications receiving 178 citations.
Papers
More filters
Journal ArticleDOI
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Denise Toscani,Carla Palumbo,Benedetta Dalla Palma,Marzia Ferretti,Marina Bolzoni,Valentina Marchica,Paola Sena,Eugenia Martella,Cristina Mancini,Valentina Ferri,Federica Costa,Fabrizio Accardi,Luisa Craviotto,Franco Aversa,Nicola Giuliani +14 more
TL;DR: Osteocyte autophagy is identified as a new potential target in MM bone disease and the use of PIs to maintain osteocyte viability and improve bone integrity in MM patients is supported.
Journal ArticleDOI
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20
B Dalla Palma,Daniela Guasco,Mario Pedrazzoni,Marina Bolzoni,Fabrizio Accardi,Federica Costa,Gabriella Sammarelli,Luisa Craviotto,M. De Filippo,Livia Ruffini,Paola Omedè,Roberto Ria,Franco Aversa,Nicola Giuliani +13 more
TL;DR: The relationship between bone disease and the BM cytokine and chemokine patterns highlighting the tight relationship between CCL20 BM levels and osteolysis in multiple myeloma patients is defined.
Journal Article
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carmelo Carlo-Stella,Lina Mangoni,Camillo Almici,D. Garau,Luisa Craviotto,Giovanna Piovani,Cecilia Caramatti,Vittorio Rizzoli +7 more
TL;DR: The absence of any detrimental effect on marrow engraftment in vivo supports the safety of the CFU-Blast assay to evaluate the dose of mafosfamide used for marrow purging before ABMT.
Journal ArticleDOI
Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.
Elena Masselli,Cecilia Carubbi,Giuliana Gobbi,Prisco Mirandola,Daniela Galli,Silvia Martini,Sabrina Bonomini,Monica Crugnola,Luisa Craviotto,Franco Aversa,Marco Vitale +10 more
TL;DR: It is demonstrated that PMF megakaryocytic cultures express higher levels of PKCɛ than healthy donors, which correlate with higher disease burden but not with JAK2V617F mutation, and represents a proof-of-concept for PKC∛ inhibition as a novel therapeutic strategy in PMF.
Journal ArticleDOI
CD14+CD16+ monocytes are involved in daratumumab‐mediated myeloma cells killing and in anti‐CD47 therapeutic strategy
Paola Storti,Rosanna Vescovini,Federica Costa,Valentina Marchica,Denise Toscani,Benedetta Dalla Palma,Luisa Craviotto,Fabio Malavasi,Nicola Giuliani +8 more
TL;DR: It is found that the ratio between monocytes (CD14+) and MM cells (CD138+) influences the response to DARA, which underlines the critical role of the CD16+ monocytes in DARA anti‐MM killing effects and gives a rationale to test the combination of an anti‐CD47 mAb with anti-CD38 mAbs.